MENU
Sri Lanka to start GMRx2 implementation project funded by NIHR
GMRx2 Trial
A novel low-dose, 3 in 1 pill called GMRx2 demonstrated significant efficacy in blood pressure reduction http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01744-6/abstract. . The study compared the efficacy and safety of the combination of telmisartan, amlodipine, and indapamide against placebo and dual combinations of these components. The GMRx2 group achieved a 74% success rate in reducing the blood pressure to<140/90 mmHg, compared to the dual-combination groups. This significant finding earned recognition at the European Society of Cardiology Congress 2024. Following this, George Medicines https://george-medicines.com/, funder of the GMRx2 trial, signed an exclusive licensing deal with Bausch Health to commercialize GMRx2 in Canada, Mexico, Colombia, and Central America.
The NIHR (National Institute for Health and Care Research), UK funds and supports health and social care research, aiming to improve people’s health and well-being. Building on the success of the GMRx2 trial, the project “A Low-Cost, Scalable Treatment Strategy for Improving Hypertension Control in Low and Middle-Income Settings” has received a grant from the NIHR. This initiative will focus on integrating the GMRx2 treatment into primary care hospitals in Sri Lanka and Nigeria, where hypertension is a major public health challenge.
The grant for the project was secured through the joint efforts of:
Professor Otavio Berwanger – Imperial College of Science, Technology and Medicine, UK
Professor Asita de Silva – University of Kelaniya, Sri Lanka
Dr. Dike Ojji – University of Abuja, Nigeria
An implementation trial like this focuses on addressing questions beyond just the clinical effectiveness of the treatment, such as:
Next Steps
The study will evaluate the effectiveness, implementation, budget impact and cost-effectiveness of the new treatment strategy, among adults with uncontrolled BP. If proven viable, the strategy will be integrated into healthcare guidelines and policies, ensuring widespread adoption as a standard of care. RemediumOne will provide its constant support to conduct this implementation project in Sri Lanka, leveraging its dedication in maintaining the highest standards in trial management.
Join Us
Stay connected for updates on this research that aims to reshape hypertension treatment and improve global health outcomes.
